Literature DB >> 24714478

A survey of breakthrough therapy designations.

Saurabh Rob Aggarwal1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24714478     DOI： 10.1038/nbt.2864

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  22 in total

1.  Targeted cancer therapies.

Authors:  Saurabh Aggarwal
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

2.  Drugs with breakthrough status charm investors.

Authors:  Melanie Senior
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

3.  Expediting drug development--the FDA's new "breakthrough therapy" designation.

Authors:  Rachel E Sherman; Jun Li; Stephanie Shapley; Melissa Robb; Janet Woodcock
Journal:  N Engl J Med       Date:  2013-11-14       Impact factor: 91.245

4.  Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.

Authors:  Denise A Yardley; Roohi R Ismail-Khan; Bohuslav Melichar; Mikhail Lichinitser; Pamela N Munster; Pamela M Klein; Scott Cruickshank; Kathy D Miller; Min J Lee; Jane B Trepel
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

5.  Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-09

6.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.

Authors:  Jianmeng Chen; Jeffry Florian; Wendy Carter; Russell D Fleischer; Thomas S Hammerstrom; Pravin R Jadhav; Wen Zeng; Jeffrey Murray; Debra Birnkrant
Journal:  Gastroenterology       Date:  2013-03-05       Impact factor: 22.682

7.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

8.  Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.

Authors:  Gregory T Everson; Karen D Sims; Maribel Rodriguez-Torres; Christophe Hézode; Eric Lawitz; Marc Bourlière; Veronique Loustaud-Ratti; Vinod Rustgi; Howard Schwartz; Harvey Tatum; Patrick Marcellin; Stanislas Pol; Paul J Thuluvath; Timothy Eley; Xiaodong Wang; Shu-Pang Huang; Fiona McPhee; Megan Wind-Rotolo; Ellen Chung; Claudio Pasquinelli; Dennis M Grasela; David F Gardiner
Journal:  Gastroenterology       Date:  2013-10-30       Impact factor: 22.682

9.  Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Authors:  Kris V Kowdley; Eric Lawitz; Fred Poordad; Daniel E Cohen; David R Nelson; Stefan Zeuzem; Gregory T Everson; Paul Kwo; Graham R Foster; Mark S Sulkowski; Wangang Xie; Tami Pilot-Matias; George Liossis; Lois Larsen; Amit Khatri; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

10.  Novel Bruton's tyrosine kinase inhibitors currently in development.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Onco Targets Ther       Date:  2013-03-06       Impact factor: 4.147
View more
  9 in total

1.  Intact Transition Epitope Mapping (ITEM).

Authors:  Yelena Yefremova; Kwabena F M Opuni; Bright D Danquah; Hans-Juergen Thiesen; Michael O Glocker
Journal:  J Am Soc Mass Spectrom       Date:  2017-06-14       Impact factor: 3.109

2.  One-pot enzymatic glycan remodeling of a therapeutic monoclonal antibody by endoglycosidase S (Endo-S) from Streptococcus pyogenes.

Authors:  Xin Tong; Tiezheng Li; Jared Orwenyo; Christian Toonstra; Lai-Xi Wang
Journal:  Bioorg Med Chem       Date:  2017-07-29       Impact factor: 3.641

3.  FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Huan-Yu Chen; Kun He; Mona Patel; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2014-08-28

4.  Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling.

Authors:  Tiezheng Li; Xin Tong; Qiang Yang; John P Giddens; Lai-Xi Wang
Journal:  J Biol Chem       Date:  2016-06-10       Impact factor: 5.157

5.  Treatment of hypophosphatasia by muscle-directed expression of bone-targeted alkaline phosphatase via self-complementary AAV8 vector.

Authors:  Aki Nakamura-Takahashi; Koichi Miyake; Atsushi Watanabe; Yukihiko Hirai; Osamu Iijima; Noriko Miyake; Kumi Adachi; Yuko Nitahara-Kasahara; Hideaki Kinoshita; Taku Noguchi; Shinichi Abe; Sonoko Narisawa; Jose Luis Millán; Takashi Shimada; Takashi Okada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-02-03       Impact factor: 6.698

6.  Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).

Authors:  Amy S Paller; John Browning; Milos Nikolic; Christine Bodemer; Dedee F Murrell; Willistine Lenon; Eva Krusinska; Allen Reha; Hjalmar Lagast; Jay A Barth
Journal:  Orphanet J Rare Dis       Date:  2020-06-23       Impact factor: 4.123

7.  Efficient Delivery of Antibodies Intracellularly by Co-Assembly with Hexahistidine-Metal Assemblies (HmA).

Authors:  Shaoyin Wei; Sijie Zhou; Wenjuan Huang; Xingjie Zan; Wujun Geng
Journal:  Int J Nanomedicine       Date:  2021-11-06

Review 8.  Identification and Affinity Determination of Protein-Antibody and Protein-Aptamer Epitopes by Biosensor-Mass Spectrometry Combination.

Authors:  Loredana-Mirela Lupu; Pascal Wiegand; Daria Holdschick; Delia Mihoc; Stefan Maeser; Stephan Rawer; Friedemann Völklein; Ebrahim Malek; Frederik Barka; Sascha Knauer; Christina Uth; Julia Hennermann; Wolfgang Kleinekofort; Andreas Hahn; Günes Barka; Michael Przybylski
Journal:  Int J Mol Sci       Date:  2021-11-27       Impact factor: 5.923

9.  Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution.

Authors:  Siddharth Menon; Amy Davies; Sophia Frentzas; Cheryl-Ann Hawkins; Eva Segelov; Daphne Day; Ben Markman
Journal:  Cancer Rep (Hoboken)       Date:  2021-07-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.